According to the trade group Pharma Industry Finland (PIF), the working group for the reform of the medicines reimbursement system had some good proposals in its report recently handed over to Minister Paula Risikko. However, there was potential for more, it noted.
The reimbursement system took a step in the right direction as the initial patient co-payment and the decrease in the medicines expense ceiling target that support those who need many medicines. However, the proposal falls short of the objectives because it does not help the Finnish health care system keep up with the international progress. The further development work proposed by the working group must be launched rapidly, implementing it in collaboration with the pharmaceutical branch operators.
Still many challenges in safeguarding novel medicines access
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze